Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Humana and Boehringer Ingelheim Report New Findings on COPD Medication Adherence

XTALKS VITALS NEWS

Inhaler

There is no cure for COPD, however currently-available treatments aim to reduce the frequency and severity of symptoms, which include coughing, breathlessness and tightness in the chest.

Share this!

January 10, 2017 | by Sarah Hand, M.Sc.

Healthcare insurance company, Humana, and global pharmaceutical company, Boehringer Ingelheim, have found an association between medication adherence to chronic obstructive pulmonary disease (COPD) treatments and other chronic disease drugs. The findings were published in the International Journal of COPD.

COPD is a respiratory disease which progressively worsens over time. There is no cure for COPD, however currently-available treatments aim to reduce the frequency and severity of symptoms, which include coughing, breathlessness and tightness in the chest.

“Because people living with COPD are frequently diagnosed with another chronic disease, such as cardiovascular disease or diabetes, we designed this new study to explore the relationship between adherence to daily medicines for these other diseases and adherence to daily maintenance medicines for COPD,” said study co-author, Phil Schwab with Humana's Comprehensive Health Insights. “The study results showed patients who are likely to be non-adherent to other medicines are also likely to be non-adherent to their COPD medicines.”



According to the study authors, this finding suggests that non-adherence to medications for chronic conditions like COPD, could be caused by a number of factors that affect a person’s ability and willingness to take their medication as prescribed. These factors could be behavioural in nature – such as forgetfulness – or they could relate to a patient’s socioeconomic situation – including low income, low health literacy or lack of coordinated healthcare.

“These findings are important, because they help guide physicians on how best to support COPD patients with historically low adherence in taking their medications so they can achieve optimal health outcomes,” said Dr. Andrew Renda, Bold Goal Director for Humana. “Rather than focus on the number and type of comorbidities with COPD, holistic adherence improvement efforts should address access, affordability, and most importantly, education on how these medications improve symptoms and quality of life while reducing the risk of exacerbations.”

Over 15 million Americans have been diagnosed with COPD, according to the Centers for Disease Control and Prevention. COPD, along with other lower respiratory diseases, represent the third leading cause of death in the US.


Keywords: COPD, Medication Adherence, Chronic Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.